Moderna

Revolution Medicines Completes Acquisition of EQRx

Retrieved on: 
Thursday, November 9, 2023
Standard of care, RAS, Public Sector Net Cash Requirement, Stanford University, Health care, Guggenheim Partners, Moores Cancer Center, Duane J. Roth, Acquisition, University of Iowa School of Music, Moderna, Revolution, Medicine, Latham & Watkins, University, Genentech, Cancer, Investment, Patient, Goldman Sachs, Pharmaceutical industry

REDWOOD CITY, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced it has closed its acquisition of EQRx, Inc.

Key Points: 
  • Acquisition Expected to Add Approximately $1.1 Billion in Net Cash to Revolution Medicines’ Balance Sheet, Supporting Late-Stage Development of RAS(ON) Inhibitor Investigational Drugs
    REDWOOD CITY, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced it has closed its acquisition of EQRx, Inc.
  • Through the acquisition, Revolution Medicines expects to add approximately $1.1 billion in net cash proceeds to its balance sheet, after estimated post-closing EQRx wind-down and transition costs.
  • Each share of common stock of EQRx issued has been converted into the right to receive 0.1112 shares of common stock of Revolution Medicines.
  • EQRx common stock has ceased trading on the Nasdaq Global Market and all EQRx programs are being wound down.

GeoVax Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, November 8, 2023
Research, Good manufacturing practice, Vaccine, Treatment, Pfizer, COVID-19, Immunity, Alpha, SARS-CoV-2, Matrix (biology), Biotechnology, Head, HIV, Immune system, Antibody, Cancer, University, Safety, Patient, D, Immunodeficiency, CGMP, Security (finance), Conference, Chronic lymphocytic leukemia, HNSCC, City, Growth, VP40, GeoVax, Patent, FDA, AACR, Protein structure, CLL, MVA, Atrium Health Wake Forest Baptist, Infection, ABL, Fred Hutchinson Cancer Research Center, Pharmaceutical industry, Cryptocurrency, Malaria, Omicron, Moderna

ET

Key Points: 
  • ET
    ATLANTA, GA, Nov. 08, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced financial results for the third quarter ended September 30, 2023 and provided a business update.
  • GEO-CM04S1 demonstrated potent antibody and cellular immunity in immunocompromised patients in a recent publication in the journal, Vaccines, in August 2023.
  • Cash Position: GeoVax reported cash balances of $12,687,041 at September 30, 2023, as compared to $27,612,732 at December 31, 2023.
  • ET today, November 8, 2023, to review financial results and provide an update on corporate developments.

BioSpace Announces 2024 Best Places to Work in Biopharma Winners

Retrieved on: 
Tuesday, November 7, 2023
Eli Lilly, Alnylam Pharmaceuticals, Biotechnology, Amgen, The Last Best Place, Messenger, Vertex Pharmaceuticals, Culture, Therapy, Management, Pharmaceutical industry, Moderna

DES MOINES, Iowa, Nov. 7, 2023 /PRNewswire/ -- BioSpace, the leader in biopharma news and careers has published its 2024 Best Places to Work list.

Key Points: 
  • DES MOINES, Iowa, Nov. 7, 2023 /PRNewswire/ -- BioSpace, the leader in biopharma news and careers has published its 2024 Best Places to Work list.
  • The list includes 60 employers with U.S. operations that have been recognized as Best Places to Work by the life sciences community, with 30 ranked in large and small employer categories respectively.
  • "The high-level of interest we receive in Best Places to Work indicates that it is imperative employers look after their staff, culture and reputation for long-term success," said Josh Goodwin, BioSpace CEO.
  • To view the complete lists of 2024 Best Places to Work winners, click here .

GeoVax Commences Site Expansion for Phase 2 Trial of Next-Generation COVID-19 Vaccine

Retrieved on: 
Monday, October 30, 2023
Bone marrow, CAR, Immunodeficiency, Fred Hutchinson Cancer Research Center, Biotechnology, Hope, COVID-19 vaccine, City, Pfizer, COVID-19, Cancer, Messenger, GeoVax, University, Atrium Health Wake Forest Baptist, Infection, Safety, Patient, Vaccine, Moderna

ATLANTA, GA, Oct. 30, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that it has commenced the planned site expansion for the Phase 2 clinical trial investigating its next-generation SARS-CoV-2 vaccine, GEO-CM04S1, as a primary vaccine in immunocompromised patients. In addition to study enrollments completed at the City of Hope Medical Center (Duarte, California), the trial will be initiating enrollment of eligible patients at Wake Forest Baptist Medical Center (Winston Salem, North Carolina), the University of Massachusetts Medical Center (Worcester, Massachusetts), and Fred Hutchinson Cancer Research Center (Seattle, Washington).

Key Points: 
  • ATLANTA, GA, Oct. 30, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that it has commenced the planned site expansion for the Phase 2 clinical trial investigating its next-generation SARS-CoV-2 vaccine, GEO-CM04S1, as a primary vaccine in immunocompromised patients.
  • Such patients often have difficulty mounting an adequate protective antibody response after receiving currently available COVID-19 vaccines.
  • In the U.S., there are approximately 15 million individuals who, as a result of their compromised immune systems, often do not adequately respond to the current authorized vaccines.
  • These data support the progression of the Phase 2 clinical study, which includes a direct comparison to currently approved mRNA vaccines.

Carisma Presents Pre-Clinical Proof of Concept for in vivo CAR-M using mRNA platform in collaboration with Moderna at SITC

Retrieved on: 
Tuesday, October 31, 2023
CAR, Therapy, Society for Immunotherapy of Cancer, CARM, Doctor of Philosophy, Entrepreneurship, SITC, Immunotherapy, Doctor of Pharmacy, Messenger, Annual general meeting, LNP, PT, Society, Cancer, Patient, Myelocyte, Pharmaceutical industry, Vaccine, Mitsubishi Carisma, Moderna

PHILADELPHIA, Oct. 31, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that it will present new findings at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting regarding its first-of-its-kind collaboration with Moderna. The collaboration aims to bring together Carisma's chimeric antigen receptor macrophage (CAR-M) platform with Moderna's mRNA and lipid nanoparticle (LNP) technologies to generate and develop in vivo CAR-M therapeutics.

Key Points: 
  • The collaboration aims to bring together Carisma's chimeric antigen receptor macrophage (CAR-M) platform with Moderna's mRNA and lipid nanoparticle (LNP) technologies to generate and develop in vivo CAR-M therapeutics.
  • Accepted as a late-breaking presentation, " In vivo CAR-M: Redirecting endogenous myeloid cells with mRNA for cancer immunotherapy ," showcases data that demonstrate Carisma's CAR-M therapy can be directly produced in vivo, or within the body, successfully redirecting endogenous myeloid cells against tumor-associated antigens using mRNA/LNP.
  • "We are pleased to share data about the successful application of our mRNA platform to advance in vivo cell therapy," said Lin Guey, PhD, Chief Scientific Officer of External Research Ventures at Moderna.
  • Details of Carisma data accepted for presentation at the SITC 38th Annual Meeting are as follows:

Generation Bio Announces Demonstration of Highly Selective T Cell Transduction In Vivo with Cell-Targeted LNP Platform

Retrieved on: 
Thursday, October 26, 2023
Q&A, RNA, Spleen, Congress, Liver, Moderna, CEST, DNA, European Society of Gene and Cell Therapy, Tissue, Cell, Gene, Webcast, Messenger, LNP, ESGCT, Generation, Patient, NHP, Dietary supplement, Vaccine

Generation Bio will present these data at the European Society for Gene and Cell Therapy (ESGCT) 30th Annual Congress in Brussels, Belgium at 4:40 p.m. CEST today.

Key Points: 
  • Generation Bio will present these data at the European Society for Gene and Cell Therapy (ESGCT) 30th Annual Congress in Brussels, Belgium at 4:40 p.m. CEST today.
  • Slides from the presentation will be made available on Generation Bio’s website following the presentation.
  • “Furthermore, species translation for the stealth LNP underlying our ctLNP platform is highly encouraging as we continue to move forward with our cell-targeting work.
  • Registration information for the webcast R&D deep dive can be found on the Events page of Generation Bio’s investor website.

GeoVax Update: Clinical and Operational Progress Toward Transformative Opportunities

Retrieved on: 
Tuesday, October 24, 2023
Patient, FDA, Patent, Vaccine, SARS-CoV-2, Matrix (biology), Biotechnology, HIV, Conference, Data, COVID-19 vaccine, Pfizer, VP40, COVID-19, Cancer, MVA, GeoVax, Infection, Biological patent, Alpha, Safety, Pharmaceutical industry, Nursing, Malaria, Omicron, Immunodeficiency, Moderna

Enrollment Target Completed for Phase 2 Clinical Trial Evaluating GEO-CM04S1 as a Booster for Healthy Patients Who Have Previously Received the Pfizer or Moderna mRNA Vaccine.

Key Points: 
  • Enrollment Target Completed for Phase 2 Clinical Trial Evaluating GEO-CM04S1 as a Booster for Healthy Patients Who Have Previously Received the Pfizer or Moderna mRNA Vaccine.
  • GeoVax and ProBioGen announced the signing of a landmark commercial license agreement for ProBioGen’s groundbreaking AGE1.CR.pIX® suspension cell line.
  • The agreement empowers GeoVax to enhance the manufacturing capabilities of its entire Modified Vaccinia Ankara (MVA)-based vaccine portfolio.
  • GeoVax announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for Patent Application No.

More than 50 organizations choose Truveta for the most complete, timely, and clean EHR data to study safety and effectiveness, improve patient care, and train medical AI

Retrieved on: 
Monday, October 23, 2023
Patient, UCB, HS, Education, MPH, Duke University, Biomarker, Therapy, Rare, Government, Social stigma, Cirrhosis, Oncology, AUC, Organization, Hidradenitis suppurativa, Health, Research, Liver disease, Senior, Pfizer, Natural history, Disease, NASH, Boehringer Ingelheim, Partnership, Hospital, Scar, EHR, Safety, AI, Boston Scientific, Diagnosis, Fatty liver disease, Pharmaceutical industry, Nursing, Medical imaging, Wolfram Mathematica, MD, Moderna

Truveta welcomes researchers from Boehringer Ingelheim, Moderna, UCB, and others studying various diseases, drugs, and devices with Truveta’s data and analytics solutions.

Key Points: 
  • Truveta welcomes researchers from Boehringer Ingelheim, Moderna, UCB, and others studying various diseases, drugs, and devices with Truveta’s data and analytics solutions.
  • In addition to life sciences companies, Truveta also announced that Duke University will access existing Truveta Data to advance research broadly across many conditions.
  • “Truveta was founded with a singular vision of saving lives with data,” said Terry Myerson, CEO and co-founder, Truveta.
  • “The lack of available data to study patients with rare disease is the biggest challenge we face in using real-world data.

Caris Life Sciences and Moderna Announce Multi-Year Strategic Partnership to Advance mRNA-Based Oncology Therapeutics

Retrieved on: 
Tuesday, October 24, 2023
Sequence, WES, MPH, Biomarker, Therapy, Doctor of Philosophy, MBA, Data science, MRNA, Disease, Medicine, Messenger, Probability, AI, Patient, MS, Pharmaceutical industry, Medical imaging, MD, Moderna

IRVING, Texas, Oct. 24, 2023 /PRNewswire/ -- Caris Life Sciences®(Caris), the leading next-generation AI TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition using molecular science and AI, today announced a new agreement with Moderna (NASDAQ:MRNA) in support of Moderna's oncology and novel therapeutics initiatives.

Key Points: 
  • "Partnering with Caris Life Sciences will support Moderna's oncology portfolio with clinico-genomics data from Caris' industry-leading and comprehensive suite of integrated precision medicine capabilities," stated Praveen Aanur, MD, MPH, MBA, Vice President, Oncology Therapeutic Area Head of Moderna.
  • "We are thrilled to partner with Moderna to impact and advance the field of cancer treatment with mRNA medicines, with a common goal of improving patient lives," said David Spetzler , MS, PhD, MBA, President of Caris Life Sciences.
  • As the pioneer in precision medicine and molecular profiling, Caris has created the largest clinico-genomic database coupled with cognitive computing to unravel the molecular complexity of disease.
  • Caris was the first in the industry to provide Whole Exome Sequencing DNA coverage and Whole Transcriptome Sequencing RNA coverage (WES / WTS) for every patient.

Generation Bio Announces Breakthrough in its Non-Viral Genetic Medicine Platform with Novel “Immune-Quiet” DNA

Retrieved on: 
Wednesday, October 18, 2023
Q&A, American Institute, International Conference on Bioinformatics, Haemophilia, Therapy, RNA, Biotechnology, LNP, Congress, Liver, IL-6, Cytokine, Conference, American Institute of Chemical Engineers, VIII, RES, Mouse, European Society of Gene and Cell Therapy, Tissue, Cell, Gene, Webcast, Messenger, ESGCT, Generation, European Society of Clinical Microbiology and Infectious Diseases, Investment, Patient, NHP, DNA, Mobile phone, Vaccine, Moderna

CAMBRIDGE, Mass., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company developing genetic medicines for people living with rare and prevalent diseases, today announced the development of a proprietary, novel DNA called immune-quiet DNA (iqDNA). iqDNA is an optimized variant of the company’s closed-ended DNA (ceDNA) that upon systemic administration with Generation Bio’s lipid nanoparticle (LNP) delivery has shown cytokine levels and tolerability comparable to chemically modified messenger RNA (mRNA) in mice and non-human primates (NHPs).

Key Points: 
  • Generation Bio’s non-viral genetic medicine platform aims to advance durable, redosable, and titratable therapies to reach potentially hundreds of millions of patients worldwide.
  • The company has made deep investments in its three proprietary platform technologies, comprising novel DNA cargos, rapid enzymatic synthesis (RES) manufacturing, and cell-targeted LNP (ctLNP) delivery.
  • The presentation will cover the development and progress of Generation Bio’s ctLNP platform, including its stealth and targeting delivery system.
  • Registration information for the webcast can be found on the Events page of Generation Bio’s investor website.